A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

C. albicans normally grows as yeast cells (top). Genetic or pharmacological inhibition of Hst3 triggers the formation of abnormal V-shaped filaments and DNA fragmentation (bottom) that culminate in cell death.

Infections by the yeast Candida albicans represent a significant public health problem and a common complication in immunodeficient individuals such as AIDS patients, cancer patients undergoing chemotherapy and recipients of organ transplants. While some treatments are available, their efficacy can be compromised by the emergence of drug-resistant strains.

The current study shows that a C. albicans enzyme, known as Hst3, is essential to the growth and survival of the yeast. Researchers found that genetic or pharmacological inhibition of Hst3 with nicotinamide, a form of vitamin B3, strongly reduced C. albicans virulence in a mouse model. Both normal and drug-resistant strains of C. albicans were susceptible to nicotinamide. In addition, nicotinamide prevented the growth of other pathogenic Candida species and Aspergillus fumigatus (another human pathogen), thus demonstrating the broad antifungal properties of nicotinamide.

“There is an urgent need to develop new therapies to kill C. albicans because it is one of the leading causes of hospital-acquired infections and is associated with high mortality rates,” explains Martine Raymond. “Although many issues remain to be investigated, the results of our study are very exciting and they constitute an important first step in the development of new therapeutic agents to treat fungal infections without major side effects for patients.”

Researcher & Financing
Martine Raymond is Principal Investigator in the Yeast Molecular Biology Laboratory. Alain Verreault is Principal Investigator in the Chromosome Biogenesis Laboratory. Pierre Thibault is Principal Investigator in the Proteomics and Bioanalytical Mass Spectrometry Laboratory. The research received funding from the Canadian Institutes for Health Research and the National Science and Engineering Research Council of Canada.

Paper cited
Hugo Wurtele, Sarah Tsao, Guylaine Lépine, Alaka Mullick, Jessy Tremblay, Paul Drogaris, Eun-Hye Lee, Pierre Thibault, Alain Verreault and Martine Raymond. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nature Medicine, July 4, 2010; DOI: 10.1038/nm.2175

Information
Carolyne Lord
IRIC | Université de Montréal
514.343.7282
carolyne.lord@umontreal.ca